Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It

Johnson & Johnson (JNJ) shares have underperformed the S&P 500 and its industry over the past month, despite consistently beating revenue and EPS estimates in the last four quarters. While the consensus earnings estimate for the current fiscal year indicates a 6.2% year-over-year increase, the estimate for the current quarter shows a 6% decline, and the stock holds a Zacks Rank #3 (Hold), suggesting near-term performance in line with the broader market; the company is currently valued at a discount relative to its peers.

Analysis

Johnson & Johnson (JNJ) has recently garnered significant investor attention, yet its stock has underperformed, declining 2.6% over the past month in contrast to the S&P 500's 5.2% gain and against a 3.7% loss for the Zacks Large Cap Pharmaceuticals industry. Analyst earnings estimates for JNJ present a mixed near-term outlook: the current quarter's EPS is projected at $2.65, a 6% decrease year-over-year, though the consensus estimate for the current fiscal year anticipates a 6.2% increase to $10.60, and a further 3.5% rise to $10.98 for the next fiscal year. These estimates have remained unchanged over the last 30 days, contributing to JNJ's Zacks Rank #3 (Hold), which suggests the stock may perform in line with the broader market. Revenue growth projections are modest, with a consensus estimate of $22.77 billion for the current quarter (+1.4% YoY), and full-year estimates of $91.19 billion (+2.7% YoY) for the current fiscal year and $94.24 billion (+3.4% YoY) for the next. Despite the recent underperformance and muted near-term growth expectations, JNJ has a strong track record, having surpassed consensus EPS and revenue estimates in each of the last four reported quarters; in the most recent quarter, revenue reached $21.89 billion (+2.4% YoY, a 1.26% surprise) and EPS was $2.77 (a 7.78% surprise). From a valuation perspective, JNJ holds a Zacks Value Style Score of B, indicating it is currently trading at a discount relative to its peers.

Key Decisions for Investors

• Given Johnson & Johnson's Zacks Rank #3 (Hold) and the anticipated 6% year-over-year decline in current quarter EPS, investors might consider maintaining current positions, as significant near-term outperformance appears unlikely.
• The company's consistent history of exceeding earnings and revenue expectations, coupled with its current valuation at a discount to peers, may present a case for long-term investors to monitor for entry points or hold existing stakes.
• Investors should closely watch for any revisions in earnings estimates, as these are primary drivers of the Zacks Rank and could signal shifts in JNJ's near-term stock performance prospects, especially considering the currently unchanged estimates amidst projected modest revenue growth.